Released May 9, 2013, after the close
10-Q filed May 9, 2013, 39 days after period end · 0001193125-13-211191
Q1 2013 · 10-Q
Revenue$2.75M$2.75M ±0.0% vs Q1 2012+91.5% vs Q4 2012
Net Income-$16.49M-$16.49M N/M vs Q1 2012N/M vs Q4 2012
EPS Diluted-$0.11-$0.11 N/M vs Q1 2012no prior Q4 2012 on file
Gross Profit$2,357,000±0.0%
Operating Income-$6,611,000—
Operating Cash Flow-$5,331,000N/M
Margins · derived
Gross margin85.7%±0.0 pt vs Q1 2012
Operating margin-240.4%
Net margin-599.7%−216.6 pt vs Q1 2012
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2013 | Q1 2012 | Q1 2011 |
|---|---|---|---|
| Revenue | $2.75M | $2.75M | — |
| Net Income | -$16.49M | -$10.54M | -$3.84M |
| EPS Diluted | -$0.11 | -$0.52 | -$0.19 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
SELLAS Life Sciences Group, Inc. · CIK 1390478 · Engraved from SEC EDGAR